Apogee Therapeutics, Inc. (APGE)Healthcare | Biotechnology | Waltham, United States | NasdaqGM
134.97 USD
+0.01
(0.007%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 135.02 +0.05 (0.037%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 6:03 a.m. EDT
Apogee is trading at a premium valuation near its 52-week high, driven by a Blackstone partnership and clinical milestones, yet the fundamentals remain speculative with negative earnings and cash burn. The balance sheet is robust, providing a safety net, but the market consensus is to hold, reflecting uncertainty over the path to profitability. Options flow confirms this tension, with traders buying protection against a near-term pullback while betting on long-term recovery. This is a high-volatility catalyst play rather than a stable investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.400843 |
| AutoARIMA | 0.406226 |
| AutoETS | 0.416515 |
| AutoTheta | 0.431342 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 1.13 |
| Ljung-Box p | 0.998 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 35.20 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.572 |
| Market Cap | 10,215,573,504 |
| Forward P/E | -25.79 |
| Beta | 0.34 |
| Website | https://www.apogeetherapeutics.com |
As of Aug. 22, 2026, 6:03 a.m. EDT: Speculators are positioning for long-term upside with heavy call open interest in late 2026 and 2027, but are hedging near-term downside risk with significant put open interest for August 2026. Implied volatility is elevated on near-term puts, suggesting fear of a correction following the recent merger-driven surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.564712 |
| Address1 | Building 17 |
| Address2 | Suite 102b 221 Crescent Street |
| All Time High | 134.99 |
| All Time Low | 14.19 |
| Ask | 171.87 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.9 - Hold |
| Average Daily Volume10 Day | 1,250,560 |
| Average Daily Volume3 Month | 2,745,920 |
| Average Volume | 2,745,920 |
| Average Volume10Days | 1,250,560 |
| Beta | 0.343 |
| Bid | 96.59 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 15.914 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 134.97 |
| Current Ratio | 26.439 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 134.975 |
| Day Low | 134.93 |
| Debt To Equity | 0.572 |
| Display Name | Apogee Therapeutics |
| Earnings Timestamp | 1,786,365,000 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -322,120,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -28.603 |
| Enterprise Value | 9,213,715,456 |
| Eps Current Year | -4.74634 |
| Eps Forward | -5.23355 |
| Eps Trailing Twelve Months | -4.35 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 132.2104 |
| Fifty Day Average Change | 2.7595978 |
| Fifty Day Average Change Percent | 0.020872774 |
| Fifty Two Week Change Percent | 256.4712 |
| Fifty Two Week High | 134.99 |
| Fifty Two Week High Change | -0.020004272 |
| Fifty Two Week High Change Percent | -0.00014819077 |
| Fifty Two Week Low | 35.39 |
| Fifty Two Week Low Change | 99.58 |
| Fifty Two Week Low Change Percent | 2.8137894 |
| Fifty Two Week Range | 35.39 - 134.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,689,341,400,000 |
| Float Shares | 58,441,609 |
| Forward Eps | -5.23355 |
| Forward P E | -25.789377 |
| Free Cashflow | -145,624,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 261 |
| Fullday Change | 0.00999451 |
| Fullday Change Percent | 0.00740553 |
| Fullday Price | 135.02 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02315 |
| Held Percent Institutions | 1.10634 |
| Implied Shares Outstanding | 75,687,735 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-07-14 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts. |
| Long Name | Apogee Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 10,215,573,504 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1816591253 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -294,372,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,213,302,960 |
| Number Of Analyst Opinions | 11 |
| Open | 134.95 |
| Operating Cashflow | -243,894,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 394 5230 |
| Post Market Change | 0.05000305 |
| Post Market Change Percent | 0.03704753 |
| Post Market Price | 135.02 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 134.96 |
| Price Eps Current Year | -28.43665 |
| Price Hint | 2 |
| Price To Book | 8.481212 |
| Profit Margins | 0.0 |
| Quick Ratio | 26.167 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.86667 |
| Region | US |
| Regular Market Change | 0.00999451 |
| Regular Market Change Percent | 0.00740553 |
| Regular Market Day High | 134.975 |
| Regular Market Day Low | 134.93 |
| Regular Market Day Range | 134.93 - 134.975 |
| Regular Market Open | 134.95 |
| Regular Market Previous Close | 134.96 |
| Regular Market Price | 134.97 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 438,760 |
| Return On Assets | -0.20299 |
| Return On Equity | -0.32456002 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 62,201,093 |
| Shares Percent Shares Out | 0.056500003 |
| Shares Short | 4,273,438 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,133,296 |
| Short Name | Apogee Therapeutics, Inc. |
| Short Percent Of Float | 0.0728 |
| Short Ratio | 3.63 |
| Source Interval | 15 |
| State | MA |
| Symbol | APGE |
| Target High Price | 135.11 |
| Target Low Price | 133.0 |
| Target Mean Price | 134.84818 |
| Target Median Price | 135.0 |
| Total Cash | 971,926,016 |
| Total Cash Per Share | 12.888 |
| Total Debt | 6,833,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 90.499725 |
| Two Hundred Day Average Change | 44.470276 |
| Two Hundred Day Average Change Percent | 0.49138576 |
| Type Disp | Equity |
| Volume | 438,760 |
| Website | https://www.apogeetherapeutics.com |
| Zip | 2,453 |